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Abstract
Background: Recurrent head neck cancer (rHNC) is a known unfavourable prognostic condition.
The purpose of this work was to analyse our rHNC subgroup treated with salvage-intensity
modulated radiation therapy (IMRT) for curable recurrence after initial surgery alone.
Patients: Between 4/2003–9/2008, 44 patients with squamous cell rHNC were referred for IMRT,
mean/median 33/21 (3–144) months after initial surgery. None had prior head neck radiation. 41%
underwent definitive, 59% postoperative IMRT (66–72.6 Gy). 70% had simultaneous chemotherapy.
Methods: Retrospective analysis of the outcome following salvage IMRT in rHNC patients was
performed.
Results: After mean/median 25/21 months (3–67), 22/44 (50%) patients were alive with no disease;
4 (9%) were alive with disease. 18 patients (41%) died of disease. Kaplan Meier 2-year disease
specific survival (DSS), disease free survival (DFS), local and nodal control rates of the cohort were
59/49/56 and 68%, respectively.
Known risk factors (advanced initial pTN, marginal initial resection, multiple recurrences) showed
no significant outcome differences. Risk factors and the presence of macroscopic recurrence gross
tumor volume (rGTV) in oral cavity patients vs others resulted in statistically significantly lower
DSS (30 vs 70% at 2 years, p = 0.03). With respect to the assessed unfavourable outcome following
salvage treatment, numbers needed to treat to avoid one recurrence with initial postoperative
IMRT have, in addition, been calculated.
Conclusion: A low salvage rate of only ~50% at 2 years was found. Calculated numbers of patients
needed to treat with postoperative radiation after initial surgery, in order to avoid recurrence and
tumor-specific death, suggest a rather generous use of adjuvant irradiation, usually with
simultaneous chemotherapy.
Background
In deciding on postoperative irradiation in patients with
head neck cancer (HNC), the risk of recurrence as well as
the results of treatment of a recurrence are the most
important criteria. Local recurrence seems to have an
unfavourable prognosis: there is general accordance in the
literature, that success rates of salvage treatment of recur-
rent HNC (rHNC) are low. More than 50% of rHNC
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patients who undergo salvage treatment, will die after sal-
vage treatment as a direct consequence of local-regionally
recurrent disease [1-8]. There are, however, divergent data
with respect to the factors, that may influence the progno-
sis of rHNC following salvage therapy, like initial TN
stages, recurrence TN stages, primary site, recurrence sal-
vage treatment, time to recurrence, site of recurrence, or
resection margins, respectively [1-6,8-10].
The comparability of reported results in the literature is
limited, as examined collectives substantially differ with
respect to initial TN stages, initial as well as recurrence
treatment strategies, or primary site, respectively. Further-
more, the sample size of most reported collectives is
small.
Recent publications report a marked improvement of
local-regional control after intensity modulated radiation
therapy (IMRT) in the initial treatment of HNC [11-18].
We analysed the outcome of our definitively or postoper-
atively treated IMRT subgroup referred for local or
regional recurrence after initial surgery alone, in order to
evaluate the salvage rate following modern treatment
methods.
Patients
Between 4/2003 and 9/2008, 44 patients with rHNC were
referred for IMRT to the Department of Radiation Oncol-
ogy, University Hospital Zurich, mean/median 33/21 (3–
144) months after initial surgical treatment. The rHNC
subgroup represents 8% (44/530) of all IMRT patients
who were referred for a curatively intended irradiation of
a squamous cell HNC during the indicated time period.
None of the rHNC patients had prior radiation therapy of
the HN region.
Mean age at diagnosis of rHNC was 64.3 years (35–87).
The male to female ratio was ~2:1 (28 :16). Tumor related
parameters are listed in Table 1a and 1b.
In order to retrospectively assess parameters that could
help to predict outcome following salvage therapy, we
assessed generally accepted prognostic parameters like
early vs more advanced TN stages, histo-pathological
grading, the number of prior recurrences, resection status
(close vs wide margins), diagnosis, and, in addition, the
location of recurrence (nodal vs primary), respectively.
Methods
Several disease related factors were analysed with respect
to their prognostic impact on outcome following salvage
therapy. Considering the small sample size (n = 44), sin-
gle risk factors were grouped to 'high risk' vs 'low risk' fea-
tures (Table 2).
Salvage treatment of rHNC
In 18/44 (41%) rHNC, definitive salvage IMRT was per-
formed, 26 (59%) patients underwent IMRT following
salvage surgery of recurrent primary and/or nodal disease.
All 26 postoperative IMRT patients underwent macro-
scopically complete salvage surgery (R1-R0), however, in
12/26 patients, the planning computed tomography
(planning-CT) showed already re-grown nodal or local
recurrence gross tumor volume (rGTV). Re-staging and re-
resection in all but 2 patients have been performed by sur-
gical experts of the associated clinics of maxillofacial or
head neck surgery at the University Hospital Zurich. Re-
staging was based on clinical examination, histopatholog-
ical confirmation of the lesions, and computed tomogra-
phy and/or magnetic resonance imaging and/or positron
emission tomography in all patients. The mean interval
between salvage surgery and postoperative salvage IMRT
was 5 weeks (3–8).
IMRT was performed according to our institutional stand-
ard schedules, that are routinely used for IMRT of initial
HNC disease in curative intention: for postoperative IMRT
(+/- systemic therapy), this is 66 Gy in 33 fractions to the
boost volume (5×/week), for definitive IMRT (+/- sys-
temic therapy), schedules with 33× 2.11-2.2 Gy (5×/
week), or 35× 2.0 Gy (5–6×/week), respectively, are used.
Postoperative patients with re-grown rGTV detectable in
the planning computed tomography were treated like the
'definitive IMRT' subgroup (i.e. with tumor doses up to
70–72.6 Gy).
All schedules are based on simultaneously integrated
boost (SIB) delivery [15]. In ~70%, simultaneous systemic
therapy was given (in 27/44 cisplatin (40 mg/m2/w), in
3/44 erbitux (3–6 cycles: 1×400 mg/m2 and 2–5×250 mg/
m2/w; indications: contraindications against cisplatin,
intolerance of cisplatin).
Statistics
Actuarial survival data were calculated using Kaplan-Meier
curves implemented in StatView® (Version 4.5). p values <
0.05 were considered statistically significant.
Results
After mean/median 25/21 months (3–67) following sal-
vage IMRT, 22/44 patients (50%) were alive with no evi-
dence of disease when last seen; 4 (9%) were alive with
disease, respectively. 18 patients (41%) died from disease
mean 9.8 months (1.3–29) after salvage treatment. Dis-
ease specific survival (DSS), disease free survival (DFS),
local and nodal control rates of the entire cohort follow-
ing IMRT were 59/49/56 and 68% at 2 years, respectively
(calculated using Kaplan-Meier survival curves, Figure 1).Radiation Oncology 2008, 3:43 http://www.ro-journal.com/content/3/1/43
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Table 1: 
a Tumor related parameters
Parameters n (%)
Diagnosis
oral cavity 29 (66)
glottic 8 (18)
lateral oropharynx 4 (9)
sinonasal 2 (5)
skin 1 (2)
initial resection
wide (>2 mm, RO) 13
marginal (R1) 16
intralesional (R2) 0
unknown 15
initial pT
pT1 14
pT2 23
pT3 1
pT4 3
unknown 3
initial p/cN
N0 26
N1 5
N2a/b 9
N2c 2
unknown 2
initial grading
G1 6
G2 15
G3 12
unknown 11
grading recurrence
G1 2
G2 21
G3 11
unknown 10
No. recurrence
1st 31
2nd 8
3rd 4
4th 1
site of recurrence
nodal 14
mucosal 16
nodal and mucosal 14
Tumor characteristics in 44 patients referred for recurred squamous cell carcinoma of the head neck (rHNC).
b Tumor related parameters
rTN rN0 rN1 rN2ab N2c Total
rT0 0455 14Radiation Oncology 2008, 3:43 http://www.ro-journal.com/content/3/1/43
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Known unfavourable factors per se, like advanced initial
pTN stages (n = 13), initial marginal resection (R1, n =
16), or >1 recurrence prior to salvage radiation (n = 13),
did not result in statistically significant outcome differ-
ences. The combination of these factors ('high risk ', Table
2), as well as presence of visible recurrence gross tumor
volume (rGTV) in the planning CT (n = 30), were tenden-
tially unfavourable predictors for DSS or DFS (p ~0.1
each).
Significant statistical 2-year local control (LC) rates and
DSS differences were found for 'high risk profile' OCC
patients (risks as listed in Table 2) with measurable rGTV
(n = 14) vs others (n = 30; 30 vs 60% (p = 0.05), and 30
vs 70%, p = 0.03).
The site of recurrence (nodal (n = 14) vs mucosal (i.e. pri-
mary site) +/- nodal (n = 30)) showed a non- significant
DSS difference in favour of patients with nodal recurrence
only (~80 vs ~40% at 2 years, Figure 2).
Kaplan Meyer 2-year DFS/DSS rates did not differ for rT0-
2rN0-2b vs rT3-4rN0-2c or rT0-2 vs rT3-4, or rN stages, or
primary vs postoperative salvage IMRT, respectively.
The potential impact of concomitant systemic therapy
could not be evaluated based on this small series with dif-
ferent local treatment approaches (Table 3).
Discussion
- Outcome following salvage treatment
The presented cohort was fairly homogeneous with
respect to the previous surgical treatment and performed
IMRT with 66–72.6 Gy, respectively. As expected, at the
time of primary surgery, the majority of patients presented
with an early stage of cancer (32/44 </= pT2N2a (73%), 5
unknown).
Limitations of the study are the small sample size and
short follow up; however, the number of re-recurrent
events was high with 18 local, 14 nodal, and 4 distant fail-
ures (36 events in 22 patients), that mostly occurred dur-
ing the first year post salvage therapy (33/36, 92%).
2-year DSS and local control following salvage treatment
in the entire collective were as low as ~50% (Figure 1),
comparable to the outcome in our IMRT patients treated
with primary radio-chemotherapy for a very large initial
primary GTV of >70cc [19]. The presented outcome after
definitive as well as postoperative salvage IMRT confirms
reported general re-recurrence rates after salvage radiation
therapy in non-IMRT cohorts [1-8].
Inferior salvage outcome in recurred OCC primaries is
reported from other centres [2,4]. The combination of ini-
tial 'high risk' profile plus measurable rGTV in OCC
revealed to be a particularly unfavourable prognostic con-
stellation with respect to DSS, DFS and local control in
our cohort; the collective is too small yet to perform anal-
yses according to the different diagnoses, although there is
already a tendency to inferior outcome for OCC – in
accordance to the formerly reported inferior outcome of
OCC vs other entities in the initial treatment setting [20].
Non-OCC patients with widely resected early stage initial
disease, that underwent macroscopically radical salvage
surgery and postoperative IMRT for a first recurrence (n =
rT1 1001 2
rT2 1011 3
rT3 0100 1
rT4 18 2 3 0 23
rT? 0010 1
Total 20 7 10 7 44
Recurrence stages (rTN) of the 44 assessed patients. 23/44 (52%) presented with rT4 stage.
Table 1:  (Continued)
Table 2: Patients grouped according to risk parameters
Parameters low risk (n) high risk (n)
initial pTN </=pT2N0 or T1N0-2b (14) >pT2N0 (14)
initial resection and R0 (6) or unknown (8) and/or R1 (16)
initial grading (G) and G1-2 (7) or unknown (6) and any G
No. of recurrence and all 1st (14) any 1st (17) or (2nd–4th (13)
patients (n) 32% (14) 68% (30)
Grouped 'low' vs 'high' risk parameters in the assessed cohort.Radiation Oncology 2008, 3:43 http://www.ro-journal.com/content/3/1/43
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Local control (LC) and disease specific survival (DSS) in 44 patients treated with IMRT for recurred HNC (rHNC) Figure 1
Local control (LC) and disease specific survival (DSS) in 44 patients treated with IMRT for recurred HNC (rHNC).
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Disease specific survival (DSS) following salvage IMRT for isolated nodal recurrence vs mocosal (i.e. primary tumor) +/- nodal  recurrence Figure 2
Disease specific survival (DSS) following salvage IMRT for isolated nodal recurrence vs mocosal (i.e. primary tumor) +/- nodal 
recurrence.
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14), represented a favourable rHNC subgroup with ~70%
DSS at 2 years.
Definitive salvage radiation has been reported less effec-
tive than salvage surgery +/- postoperative radiation by
several other authors [2,3,8,21]. Our results showed no
significant difference, likely due to the small samples with
even re-grown gross tumor volumes in 12 of 26 operated
patients.
The tendency to an outcome difference between nodal vs
mucosal (i.e. primary) +/- nodal recurrence (Figure 2, p =
0.03) may confirm results by Regine et al [1]. These
authors analysed 31 rHNC patients with surgically treated
initial lesions, and found significant differences in local
control (p = 0.001) and DSS (p = 0.0001) in favour to
nodal only recurrences (n = 13).
- Numbers needed to treat to avoid recurrence
With respect to the assessed unfavourable outcome of
rHNC following postoperative or definitive salvage IMRT,
avoidance of recurrence becomes more meaningful. In
order to estimate the number needed to treat (NNT) to
avoid one recurrence with postoperative IMRT in the ini-
tial situation, NNTs have been approximatively calculated
from the here presented data (Table 4). Calculations
based on the presented recurrence rate of 50% following
salvage treatment (row 'cure rate' in the table). For initial
situations with estimated ~10% loco-regional failure rate,
an about 10% distant spread probability was provided,
for situations with a higher loco-regional failure rate of
~30%, a higher rate of ~20% distant spread was estimated
('100-10' vs '100-20 patients', first row in the table). The
estimated loco-regional recurrence rate bases on own data
on our postoperatively IMRT-treated patient cohort [16].
For favourable initial pT1-2N0M0 stage patients, recur-
rence rates of ~10–20% and more are reported in recent
surgical literature [21-24]. Provided an accepted recur-
rence rate of ~10%, most early stage HNC patients should,
in consequence, undergo initial postoperative radiation.
The calculated NNT are, – considering also the improved
treatment tolerance following IMRT [15,25-28]-, sugges-
tive for initial postoperative IMRT in most early stage
Table 3: Patients listed according to the performed different treatment modalities
Treatment modality n failures after salvage treatment (22/44)
Biopsy only + IMRT 53  o f  5
Biopsy only + IMRT + Cisplatin (10) or Erbitux (3) 13 8 of 13
R0-1 resection + IMRT 30  o f  3
R0-1 resection + IMRT + Cisplatin 11 5 of 11
R0-1 resection with GTV in Pl-CT + IMRT 43  o f  4
R0-1 resection with GTV in Pl-CT + IMRT + Cisplatin 83  o f  8
All 44 rHNC patients, analysed according to the performed salvage treatment modalities. The numbers per treatment modality arm are too small 
to draw reliable conclusions with respect to the impact of concomitant chemotherapy.
Pl-CT: Planning-computed tomography
Table 4: Numbers needed to treat (NNT)
N patients treatment estimated loco-reg RR (examples) n R n treated R cure rate R (n) survival (n) NNT
100 OP only 10% 10 10 50% (5) 95% (95) 21
100 postop RT 5% 0.5 0.5 50% (0.25) 99.75% (99.75)
100 – 10 M+ OP only 10% 10 10 50% (5) 85% (85) 21
100 – 10 M+ postop RT 5% 0.5 0.5 50% (0.25) 89.75% (89.75)
100 OP only 30% 30 30 50% (15) 85% (85) 8
100 postop RT 15% 5 5 50% (2.5) 97.5% (97.5)
100 – 20 M+ OP only 30% 30 30 50% (15) 65% (65) 8
100 – 20 M+ postop RT 15% 5 5 50% (2.5) 77.5% (77.5)
Estimated numbers needed to treat (NNT), calculated for two populations with an estimated risk for recurrence (RR) of 10% (white) or 30% 
(grey), respectively (RR of 5% in postoperative IMRT cohorts has been derived from the own postoperative IMRT pT1-2 -fraction [16]). The 
calculations were performed each with and without considering the distant metastasis (M+) fraction; the percentage of M+ was based on the 
observed M+ rate in the own IMRT population; with higher local-regional risk (e.g. 30%), the M+ rate is usually also expected increasing (e.g. ~20%). 
This data suggest the generous indication for postoperative IMRT in initial situations with estimated RR exceeding ~10–15%.
n treated R: number of treated recurrences (idealised value, as not all rHNC patients can undergo salvage treatment with curative intention 
[6,8,29]).Radiation Oncology 2008, 3:43 http://www.ro-journal.com/content/3/1/43
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HNC (except of glottic tumors), especially in OCC prima-
ries.
Conclusion
A low DSS rate of only 50% at 2 years following primary
or postoperative salvage IMRT has been assessed. Based
on the calculated NNT, we recommend initial postopera-
tive irradiation +/- chemotherapy, if the estimated risk of
local-regional recurrence after initial surgery alone
exceeds ~10%.
Abbreviations
rHNC: Recurrent head neck cancer; IMRT: intensity mod-
ulated radiation therapy; rGTV: recurrence gross tumor
volume; DSS: disease specific survival; DFS: disease free
survival; CT: computed tomography; OCC: oral cavity
cancer; NNT: numbers needed to treat.
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